Stockreport

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data [Seeking Alpha]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF NBI-1065845 may offer some advantages over currently approved MDD therapies, such as Auvelity from Axsome Therapeutics and Spravato from Johnson & Johnson. The global [Read more]